Journal Article

DZNE-2026-00799

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Prognostic value of plasma %p-tau217 in cognitively unimpaired older adults.

Silva-Rodríguez, J. ; Zhang, L. ; Kleineidam, L.DZNE* ; López-González, F. J. ; Wagner-Reguero, S. ; Martínez-Castillo, M. ; Sogorb-Esteve, A. ; Guamán-Chulunchana, M. E. ; Pastor, A. B. ; Moreno, N. ; Ruiz-Calvo, A. ; Sánchez-Martín, C. ; Alfayate, E. ; Molero-Cartón, M. ; Valeriano-Lorenzo, E. L. ; Frades-Payo, B. ; Valentí, M. ; Zea-Sevilla, M. A. ; Moscoso, A. ; Ramírez, A.DZNE* ; Martino-Adami, P. ; Riedel-Heller, S. G. ; Scherer, M. ; Jeromin, A. ; Calero, M. ; Del Ser, T. ; Schneider, A.DZNE* ; Grothe, M. J. ; Sánchez-Juan, P.

2026
Wiley Hoboken, NJ

This record in other databases:    

Please use a persistent id in citations: doi:10.1002/alz.71599

Abstract: We evaluated the prognostic value of baseline plasma phosphorylated tau 217 ratio (%p-tau217) for predicting long-term progression in cognitively unimpaired (CU) older adults.We analyzed 982 community-dwelling individuals followed annually for up to 12 years. Baseline %p-tau217 levels were quantified by mass spectrometry and stratified into four strata using previously defined cut-offs. Outcomes included longitudinal changes in cognition, neurodegeneration, and progression to mild cognitive impairment (MCI)/dementia. Results were replicated with immunoassays in the same and an independent primary care cohort (n = 1204).Participants with Elevated/High %p-tau217 exhibited accelerated cognitive decline, hippocampal atrophy, and significantly higher risks of progression to MCI (hazard ratio [HR] > 6.0) and dementia (HR > 9.9). The Low group demonstrated a 92.2% 10-year negative predictive value for any progression.Our results suggest that %p-tau217 is a robust prognostic biomarker, accurately distinguishing CU individuals at minimal risk from those at high risk of future AD-related clinical and neurodegenerative decline. Similar performance was achieved by immunoassays.

Keyword(s): Humans (MeSH) ; tau Proteins: blood (MeSH) ; Prognosis (MeSH) ; Female (MeSH) ; Disease Progression (MeSH) ; Aged (MeSH) ; Male (MeSH) ; Biomarkers: blood (MeSH) ; Cognitive Dysfunction: blood (MeSH) ; Cognitive Dysfunction: diagnosis (MeSH) ; Dementia: blood (MeSH) ; Dementia: diagnosis (MeSH) ; Phosphorylation (MeSH) ; Longitudinal Studies (MeSH) ; Aged, 80 and over (MeSH) ; MCI ; amyloid ; biomarkers ; plasma ; preclinical Alzheimer's disease ; tau Proteins ; Biomarkers

---

Contributing Institute(s):

1. Neuropsychology (AG Wagner)
2. Patient Studies (Bonn) (Patient Studies (Bonn))
3. Translational Dementia Research (Bonn) (AG Schneider)

Research Program(s):

1. 353 - Clinical and Health Care Research (POF4-353) (POF4-353)

Appears in the scientific report 2026

---

Database coverage:
; ; ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; DEAL Wiley ; Essential Science Indicators ; IF >= 10 ; JCR ; PubMed Central ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---